OBJECTIVE: Sluggish cognitive tempo (SCT), also referred to as cognitive disengagement syndrome (CDS), is characterized by symptoms such as mental fogginess, slowed behavior, daydreaming, and reduced alertness. It is increasingly recognized as a construct distinct from attention-deficit/hyperactivity disorder (ADHD). This systematic review and meta-analysis aimed to evaluate the effectiveness of pharmacological interventions on SCT/CDS-related outcomes.
